In a candid exchange with the University of Minnesota, Dr. Mark Schneiderhan, an associate professor and psychiatric pharmacist at the university's College of Pharmacy, recently unpacked some of the misconceptions surrounding mental health medications. Schneiderhan's insights provide clarity on the true nature of psychiatric medication, the appropriate use cases, and the importance of comprehensive treatment plans. According to the University of Minnesota's publication, the U.S. Centers for Disease Control and Prevention estimate that one in four adults takes a prescription medication for their mental health monthly.
In the discussions with the University of Minnesota, Schneiderhan emphasized that when prescribed and used correctly, mental health medications "do not negatively change a person’s personality" and are generally not habit-forming, two common fears among patients. Contrary to some beliefs, these medications are not designed to provide an immediate cure but to manage symptoms over time. Furthermore, sustaining treatment over a significant period after experiencing relief, ideally for at least a year, is often advised to avoid the recurrence of symptoms. Schneiderhan's clarification on these points aims to alleviate concerns that may prevent individuals from seeking or adhering to appropriate remedies.
Regarding the medications themselves, antidepressants such as sertraline, more widely known as Zoloft, rank high on the list of prescriptions for anxiety and depressive disorders. Dr. Schneiderhan also pointed to antipsychotics and stimulants as common treatments, sometimes utilized in tandem to stabilize complex conditions. He advocates for more extensive research into off-label medication usage, reflecting a growing need for nuanced treatment options for those grappling with mental illness.
Dr. Schneiderhan highlighted the lag time that is often encountered when initiating or adjusting medications, underscoring the importance of not discontinuing treatment prematurely. "About half of people who quit taking their antidepressants too soon have a relapse of depression symptoms within the next six months," he told the University of Minnesota. For those seeking additional support, organizations like the National Alliance on Mental Illness (NAMI) offer vital resources and education on mental health medications.
The professor's work extends beyond the classroom and into applied research, where he assesses the outcomes of Comprehensive Medication Management (CMM) in improving patient care. His research delves into optimally managing medications and mitigating adverse effects while promoting interprofessional care coordination. The University of Minnesota College of Pharmacy, where Schneiderhan is a prominent figure, continues to play a critical role in advancing pharmaceutical education and research in support of mental health treatment strategies.
